Compare IONQ Inc (IONQ) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance

IONQ trades at $34.73, down 4.25% today, with a bearish technical signal despite recent earnings beats. The quantum computing company shows explosive revenue growth (2025: $130M, 2026: $246M) but faces significant profitability challenges with a -553% net income margin. Analyst consensus is split with a $65.20 price target suggesting 88% upside potential, while technical indicators show oversold conditions with RSI at 26.86.

The stock presents high-risk, high-reward potential with Wall Street divided on its path to profitability. Key catalysts include quantum technology adoption and manufacturing scaling, while risks center on cash burn and competitive threats in the emerging quantum computing space.

SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.

Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.